Viruses and human cancers
Ref. 96012
- Duration: 9 weeks
- Effort: 27 hours
- Pace: ~3 hours/week
The MOOC offers a broad overview of the state of knowledge on viruses associated with cancer, the different mechanisms of carcinogenesis, the host immune response and progress in preventing tumors.
- Enrollment
- From March 2, 2023 to July 5, 2023
- Course
- From May 16, 2023 to July 11, 2023
- Languages
- English and french
What you will learn
At the end of this course, you will be able to:
- Describe about the biology and the replicative cycle of viruses associated with cancers.
- Explain the mechanism of tumorigenesis induced by these viruses.
- Define the role of the immune system in controlling these viruses and the induced tumors.
- Discuss new advances in terms of vaccination and anti-tumor therapies.
Description
About 20% of human cancers are induced by viruses, particularly in low/middle income countries, to a point that in some regions of the world, viral infection is the main etiology of human cancers. Our understanding of the relationship between viral infection and oncogenesis has considerably improved during the last two decades. As obligatory intracellular parasites, viruses encode proteins that reprogram host cellular signaling pathways that control proliferation, differentiation, cell death, genomic integrity, and recognition by the immune system. Both DNA and RNA viruses have been linked with human cancers.
Epstein-Barr virus, papillomaviruses, hepatitis B virus, human herpesvirus-8 and Merkel cell polyomavirus are the five DNA viruses that are capable of causing the development of human cancers. Human T lymphotrophic virus type 1 and hepatitis C virus are the two RNA viruses that contribute to human cancers. Treatment and prevention strategies critically depend on the double understanding of the mechanism of cell tumorigenesis and the way they are influenced by viruses.
During this MOOC, we will review the different mechanisms of virus induced carcinogenesis, from direct integration of the virus in the genome to non-specific inflammation and immune disorders. The epidemiology and specificity of each type of virus and of the induced tumor will then be given in detail. At the end we will report innovations in the prevention of virus induced tumors.
Format
This MOOC is composed of 7 teaching chapters. Each chapter has 2 to 6 sequences. Each sequence consists of a video of about 10 minutes and some MCQs so that students can test their knowledge. The videos are in English with French and English subtitles.
Prerequisites
This MOOC is open to anyone interested in cancer-associated viruses, with a good scientific background. A bachelor's degree in the sciences is recommended.
Assessment and certification
To follow this course, you can choose between two options:
- The Discovery Course gives access to videos, quizzes and discussions in the forum. No certificate is issued for this course. Registration is free.
- The Qualifying Course leads to a certificate. In addition to the activities of the Discovery Course, you will have to take a one-hour supervised distance learning exam, consisting of 30 multiple-choice questions (MCQs) and obtaining 18 correct answers. The registration fee for the Qualifying Course is 150€.
Successful completion of the Qualifying Course gives you the opportunity to apply for the Institut Pasteur Online Diploma of Infectious Diseases (DNM2IP), which consists of 5 certificates to Institut Pasteur MOOCs on infectious diseases. To learn more, visit the Institut Pasteur's web page dedicated to this diploma.
Course plan
- C1.1 : Introduction / Christian Bréchot (Institut Pasteur)
- C1.2 : Mechanisms of viral oncogenesis / Jean-Christophe Pagès (EFS, Tours)
- C1.3 : Mechanisms of Oncogenesis, Pathogenesis and Immune Evasion / Philippe Afonso (Institut Pasteur)
- C1.4 : Human oncogenic viruses and centrosomes / Chloé Journo (ENS, Lyon)
- C1.5 : Integration of viruses and cancers / Francesca di Nunzio (Institut Pasteur)
- C2.1 : Inflammation and cancer / Angela Santoni (Institut Pasteur, Roma)
- C2.2 : Viruses, immunity and cancers / Daniel Scott-Algara (Institut Pasteur)
- C2.3 : Viral stress, mutations and cancers / JP Vartanian (Institut Pasteur)
- C2.4 : Interactome, viruses and cancer / Yves Jacob (Institut Pasteur)
- C3.1 : Epidemiology of HTLV1 / Antoine Gessain (Institut Pasteur)
- C3.2 : Viral oncogenesis as a subversion of viral multiplication / Renaud Mahieux (ENS Lyon)
- C3.3 : Mechanisms of Mother to Child transmission of the oncogenic virus HTLV-1 through breastfeeding / Pierre-Emmanuel Ceccaldi (Institut Pasteur)
- C3.4 : Endogenous retroviruses / David Ribet (Inserm Rouen)
- C4.1 : Epidemiology of human papillomavirus / Antoine Touzé (University of Tours)
- C4.2 : Human papillomavirus infection and disease / John Doorbar (University of Cambridge, UK)
- C4.3 : Oncogenic human papillomaviruses / John Doorbar (University of Cambridge, UK)
- C4.4 : Merkel polyomavirus / Hélène Laude (Institut Pasteur)
- C5.1 : Epidemiology of HVB/HCV related HCC / Pierre Nahon (Université Sorbonne Paris Nord, Hôpital Avicenne)
- C5.2 : Mechanisms of HBV/HCV-induced HCC / Pascal Pineau (Institut Pasteur)
- C5.3 : HBV-HCV/HIV related HCC / Jean-Charles Duclos-Vallée (Université Paris-Saclay, Hôpital Paul-Brousse, APHP)
- C5.4 : Universal hepatitis B vaccination: a way to eliminate hepatocellular carcinoma? / Marie-Louise Michel (Institut Pasteur)
- C5.5 : Modeling hepatitis virus infections and treatment strategies in humanized mice / Hélène Strick-Marchand (Institut Pasteur)
- C5.6 : Hepatitis viruses and lymphoma / Olivier Hermine (Paris-Descartes)
- C6.1 : Oncogenic gamma-herpesviruses / Anna-Teresa Palamara (La Sapienza University of Rome, It)
- C6.2 : Herpesviruses, general introduction / Bernard Mariamé (ITAV Grenoble)
- C6.3 : Epidemiology of HHV8 / Antoine Gessain (Institut Pasteur)
- C6.4 : Kaposi’s Sarcoma and HHV8 / Roberta Santarelli (La Sapienza University of Rome, It)
- C7.1 : Therapeutic DNA vaccine against cancer / Pierre Langlade-Demoyen (Invectys, Institut Cochin)
- C7.2 : Oncolytic viruses Oncolytic viruses: a new class of immunotherapy drugs / Frédéric Tangy (Institut Pasteur)
Other course runs
Archived
- From Jan. 7, 2019 to May 13, 2019
- From Sept. 3, 2021 to Oct. 31, 2021
Course team
Jean-Pierre Vartanian
Categories
Jean-Pierre Vartanian is Associate Professor at Institut Pasteur and Team Leader of the Molecular Retrovirology Unit.
Rodolphe Suspene
Categories
He is an expert researcher in the Virology Department of the Institut Pasteur, with expertise in molecular biology and virology.
Organizations
License
License for the course content
Attribution-NonCommercial-NoDerivatives
You are free to:
- Share — copy and redistribute the material in any medium or format
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
License for the content created by course participants
All rights reserved
"All rights reserved" is a copyright formality indicating that the copyright holder reserves, or holds for its own use, all the rights provided by copyright law.